Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Oncology·MeSH: Breast Neoplasms
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Compare drugs
Frequently asked questions
How many drugs are in development for Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer?
BioSniper tracks 2 drugs in development for Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer across 1 company.
How many clinical trials target Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer?
There are 1 clinical trial targeting Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer tracked by BioSniper.
What is the prevalence of Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer?
The estimated prevalence of Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer is approximately 287.0 per 100,000 population.
Deep-dive into Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis